propulsive

(redirected from Prokinetic)
Also found in: Thesaurus, Medical, Legal, Wikipedia.

pro·pul·sion

 (prə-pŭl′shən)
n.
1. The process of driving or propelling.
2. A driving or propelling force.

[Medieval Latin prōpulsiō, prōpulsiōn-, onslaught, urging on, from Latin prōpulsus, past participle of prōpellere, to drive forward; see propel.]

pro·pul′sive, pro·pul′so·ry (-sə-rē) adj.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Adj.1.propulsive - having the power to propel; "propulsive coefficient"
2.propulsive - tending to or capable of propelling; "propellant fuel for submarines"; "the faster a jet plane goes the greater its propulsive efficiency"; "universities...the seats of propulsive thought"
dynamic, dynamical - characterized by action or forcefulness or force of personality; "a dynamic market"; "a dynamic speaker"; "the dynamic president of the firm"
Translations
References in periodicals archive ?
Summary: The dietary supplements and anti-emetic medications are expected to generate significant revenue over the forecast in the global hyperemesis gravidarum treatment market, followed by prokinetic agents.
Gastrointestinal prokinetic agents, such as erythromycin or metoclopramide, may be administered to speed gastric emptying.
Antacids, H2 receptor antagonists and prokinetic agents have had a long history of use in this area but have been found to be ineffective.
Prucalopride, a serotonin type 4 receptor agonist, is a gastrointestinal prokinetic agent that stimulates colonic peristalsis, increasing bowel motility.
Conventional drug therapy included primary disease treatment, anti-inflammatory, anti-infection, nutritional support, prokinetic agents treatment, and symptomatic treatment.
- Beijing, Shanghai-based biopharmaceutical company Sinovant Sciences and Menlo Park, California-based biopharmaceutical company Renexxion have initiated a collaboration to pursue the development of naronapride, an investigational gastrointestinal prokinetic, in Greater China, the companies said.
Prokinetic (promotility) agents, such as metoclopramide, domperidone, and erythromycin, are widely used in treating symptoms of GER in older infants and appear to improve gastric emptying, reduce regurgitation, and enhance lower esophageal sphincter tone, but they do not appear to reduce GER symptoms in preterm infants.
has launched the gastrointestinal prokinetic agent Cidine in China.
In conjunction with the US FDA's fast track status, the company has completed two Phase 1 trials of LP101 demonstrating gastrointestinal prokinetic activity as shown by accelerated gastric emptying.
Erythromycin is not only an antibiotic, but also a gastric prokinetic drug.